Finoriq research workspace
BIOVIE INC. (BIVI) Historical Metrics
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat. Review BIVI fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
- Company
- BIOVIE INC. (BIVI)
- Ticker
- BIVI
- Market Cap
- $10.7M
- Latest Price
- $1.425
- Industry
- Biotech & Pharma
BIOVIE INC. (BIVI) Current Valuation Metrics
Static valuation preview for BIOVIE INC. (BIVI). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -119.5% | Net Income | TTM Q3 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -123.1% | Operating Cash Flow | TTM Q3 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 1.07x | Stockholders' Equity | Q3 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.